Status:
COMPLETED
The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis
Lead Sponsor:
Amsterdam UMC, location VUmc
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The primary goal of this research is to study the prevalence of the wearing-off effect and possible risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab with the...
Detailed Description
Ocrelizumab is a monoclonal antibody very effective for the treatment of relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Ocrelizumab is usually administered intraven...
Eligibility Criteria
Inclusion
- 18 years or older
- Diagnosis multiple sclerosis
- Use of ocrelizumab as a treatment for multiple sclerosis for a minimum of one year
Exclusion
- Unable to answer questionnaires in Dutch
- Different infusion protocol during the previous ocrelizumab infusion (e.g. 300 mg of ocrelizumab instead of 600 mg).
Key Trial Info
Start Date :
May 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2021
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT04478591
Start Date
May 12 2020
End Date
May 1 2021
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC, location VUmc
Amsterdam, North Holland, Netherlands, 1007 MB